Clinical Trial Search

Primary: Patient-level Sensitivity of Vidoflufolastat (18F) - % Sensitivity — 86.8; 90.0; 86.9 % Sensitivity

Primary: Change From Baseline to Week 24 in Opacification of Sinuses Assessed by Computed Tomography (CT) Scan Using the Lund Mackay (LMK) Score in Dupilumab Group — -6.63 Score…

Primary: Disease-Free Survival (DFS) by BICR - Treatment Part A and B — NA; NA; NA; NA Months — p=0.6676

Primary: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks — 1.11; 0.46 Exacerbation per participant per year — p=< 0.001

Primary: Percentage of Urine Tests With Negative Cannabinoid Results During Treatment — 9.4; 14.0 Percentage

Primary: Average Daily Allergic Rhinoconjunctivitis Total Combined Score (TCS) During the 2nd Peak Grass Pollen Season (PGPS) — 7.10; 5.22 score on a scale — p=0.0036

Primary: Part A: Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT) — -3.86 meters

Primary: Percentage of Treatment Responders at Month 12 — 67.0; 33.5; 52.4; 70.0 Percentage of participants — p=<0.001

Primary: Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks — 42.8; 47.6 percentage of participants

Primary: Change From Baseline in Positive and Negative Symptom Scale Total (PANSS-T) Score — -12.0; -12.3; -7.1 score on a scale

Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) — 15; 3; 1; 0…

Primary: Anti-CHIKV SNA Titer (NT80) Seroresponse Rates at Day 22 in Baseline Seronegative Participants — 87.3; 1.1 percentage of participants — p=<0.0001

Primary: First Bishop Score — 1; 1 score on a scale — p=0.618

Primary: Number of Participants With Adverse Events — 23; 59; 1; 2 Participants

Primary: Estimated Overall Survival — 0.54; 0.56; 0.54; 0.56 proportion of participants — p=0.73